Samsung Biologics Acquires Entire 2.8 Trillion KRW Stake in Epis

[Asia Economy Reporter Myung-hwan Lee] Samsung Biologics announced on the 28th that it will purchase all shares of Samsung Bioepis worth 2.8 trillion KRW held by its US partner Biogen.

Samsung Biologics will acquire all 10,341,852 shares held by Biogen for 2.7655 trillion KRW. A Samsung Biologics official explained that the purpose of the stock acquisition is to "strengthen global business competitiveness through enhancing biopharmaceutical development capabilities." Regarding funding for the acquisition, the official stated, "We will raise new funds through internal resources and capital increase, among other methods."